Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists

Thrombosis and Haemostasis

Volumn 114, Issue 4, 2015, Pages 695-701

  Ruiz Ortiz, Martín ^a   Bertomeu, Vicente ^b   Cequier, Ángel ^c   Marín, Francisco ^d   Anguita, Manuel ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

Anticoagulation; Atrial fibrillation; SAMe TT2R2 score; Time in therapeutic range; Validation

Indexed keywords

ACENOCOUMAROL; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRONEDARONE; FLECAINIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROPAFENONE; VERAPAMIL; WARFARIN; ANTICOAGULANT AGENT; VITAMIN K GROUP;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASE ASSESSMENT; COMORBIDITY ASSESSMENT; DISEASE CONTROL; FEMALE; HEART RHYTHM; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PAROXYSMAL ATRIAL FIBRILLATION; PERMANENT ATRIAL FIBRILLATION; PERSISTENT ATRIAL FIBRILLATION; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SAME TT2R2 SCORE; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TOBACCO USE; VALIDATION STUDY; AGE; ANCESTRY GROUP; ANTAGONISTS AND INHIBITORS; AREA UNDER THE CURVE; BLOOD; BLOOD CLOTTING; CLINICAL TRIAL; COMORBIDITY; DECISION SUPPORT SYSTEM; DRUG EFFECTS; DRUG MONITORING; EPIDEMIOLOGY; ETHNOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATIENT SELECTION; PROCEDURES; RISK FACTOR; SEX DIFFERENCE; SPAIN; TREATMENT OUTCOME; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; AREA UNDER CURVE; ATRIAL FIBRILLATION; BLOOD COAGULATION; COMORBIDITY; CONTINENTAL POPULATION GROUPS; DECISION SUPPORT TECHNIQUES; DRUG MONITORING; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RISK FACTORS; ROC CURVE; SEX FACTORS; SPAIN; TREATMENT OUTCOME; VITAMIN K;

EID: 84940752486     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-02-0169     Document Type: Article

References (34)

1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
2. Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost 2011; 106: 739-749.
3. Ruiz Ortiz M, Romo E, Mesa D, et al. Outcomes and safety of antithrombotic treatment in patients aged 80 years or older with nonvalvular atrial fibrillation. Am J Cardiol 2011; 107: 1489-1493.
4. Ruiz Ortiz M, Romo Peñas E, Franco Zapata M, et al. Oral anticoagulation for nonvalvular atrial fibrillation: are scientific recommendations effective and safe in daily clinical practice?. Rev Esp Cardiol 2006; 59: 688-695.
5. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010; 376: 975-983.
6. Cancino RS, Hylek EM, Reisman JI et al. Comparing patient-level and site-level anticoagulation control as predictors of adverse events. Thromb Res 2014; 133: 652-656.
7. Gallego P, Roldan V, Marín F et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013; 110: 1189-1198.
8. De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110: 1087-1107.
9. Le Heuzey JY, Ammentorp B, Darius H, et al. Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. Thromb Haemost 2014; 111: 833-841.
10. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14: 1385-1413.
11. Miller CS, Grandi SM, Shimony A et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012; 110: 453-460.
12. Ruff CT, Giugliano RP, Braunwald E et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955-962.
13. Apostolakis S, Sullivan RM, Olshansky B, et al. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest 2013; 144: 1555-1563.
14. Lip GY, Haguenoer K, Saint-Etienne C, et al. Relationship of the SAMe-TT2R2 score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest 2014; 146: 719-726.
15. Gallego P, Roldán V, Marin F, et al. SAMe-TT2R2 Score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med 2014; 127: 1083-1088.
16. Abumuaileq RR, Abu-Assi E, Raposeiras-Roubin S, et al. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a realworld cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists. Europace 2015; Epub ahead of print.
17. Skov J, Bladbjerg EM, Bor MV, et al. SAMe-TT2R2 does not predict time in therapeutic range of the international normalized ratio in patients attending a high-quality anticoagulation clinic. Chest 2014; 145: 187-188.
18. Poli D, Antonucci E, Testa S, et al. A prospective validation of the SAMe-TT2R2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. Intern Emerg Med 2014;9:443-447.
19. Anguita-Sánchez M, Bertomeu-Martínez V, Cequier-Fillat A, on behalf of CALIFA study investigators. Quality of anticoagulation with vitamin K antagonists in Spain: prevalence of poor control and associated factors. Rev Esp Cardiol 2015; Epub ahead of print.
20. Rosendaal F, Cannegiester S, Van der Meer F, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239.
21. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137: 263-272.
22. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100.
23. Ministerio de Sanidad, Servicios Sociales e Igualdad. Agencia Española de Medicamentos y Productos sanitarios. Criterios y recomendaciones generales para el uso de nuevos anticoagulantes orales en la prevención del ictus y de la embolia sistémica en pacientes con fibrilación aurícular no valvular. Informe de posicionamiento terapéutico UT/V2/18122012. 19 de Diciembre de 2012.
24. Proietti M, Lip GYH. Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2 score. Eur Heart J Cardiovasc Pharmacother 2015; Epub ahead of print.
25. Fihn SD, Gadisseur AA, Pasterkamp E et al. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Thromb Haemost 2003; 90: 260-266.
26. National Institute for Health and Care Excellence. Atrial fibrillation: the management of atrial fibrillation. (Clinical guideline 180) 2014. http://guidance.nice.org.uk/CG180.
27. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation Cohort study. Eur Heart J 2012; 33: 1500-1510.
28. Potpara TS, Polovina MM, Licina MM, et al. Reliable identification of „truly low“ thromboembolic risk in patients initially diagnosed with „lone“ atrial fibrillation: the Belgrade atrial fibrillation study. Circ Arrhythm Electrophysiol 2012;5:319-326.
29. Van Staa TP, Setakis E, Di Tanna GL et al. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost 2011; 9: 39-48.
30. Abu-Assi E, Otero-Raviña F, Allut Vidal G. Comparison of the reliability and validity of four contemporary risk stratification schemes to predict thromboembolism in non-anticoagulated patients with atrial fibrillation. Int J Cardiol 2013; 166: 205-209.
31. Roldán V, Marín F, Fernández H. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a „real-world“ population with atrial fibrillation receiving anticoagulant therapy. Chest 2013; 143: 179-184.
32. Apostolakis S, Lane DA, Guo Y, et al. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol 2012; 60: 861-867.
33. Lip GY, Frison L, Halperin JL et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011; 57: 173-180.
34. Hess PL, Mirro MJ, Diener HC, et al. Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. Am Heart J 2014; 168: 239-247.